DRUG-DRUG INTERACTIONS WITH DAPAGLIFLOZIN: A REVIEW

DRUG-DRUG INTERACTIONS WITH DAPAGLIFLOZIN: A REVIEW

Registration ID: IJNRD_226711

Published ID: IJNRD2408223

DOI: Click Here to Get

HASNATH P K , Dr. SREEJITH K , THABSHIRA M , FIDA P , P P SHAHDA

Diabetes mellitus, Glycemic control, Sodium-glucose cotransporter-2 (SGLT2) Inhibitors, Type 2 diabetes mellitus, Dapagliflozin, polypharmacy, Drug-drug interactions, Optimising therapy

Diabetes mellitus presents a significant global health issue, necessitating innovative strategies to enhance patient outcomes. Effective glycemic control is crucial for mitigating the risk of complications such as diabetic nephropathy and cardiovascular disease. Traditional oral antidiabetic agents often fall short in long-term glycemic management, underscoring the need for advanced treatments. Sodium-glucose cotransporter-2 (SGLT2) inhibitors offer a novel approach for managing type 2 diabetes mellitus. These agents have demonstrated efficacy in reducing glycated hemoglobin without inducing hypoglycemia, either as monotherapy or in combination with various other glucose-lowering agents. They also provide additional benefits, such as promoting weight loss and lowering arterial blood pressure. Dapagliflozin, a highly potent, reversible, and selective SGLT2 inhibitor, has emerged as a cornerstone in the management of type 2 diabetes mellitus. It represents an attractive therapeutic option for patients whose blood glucose levels are inadequately controlled by metformin and/or other oral antidiabetic drugs (OADs), offering a complementary insulin-independent mechanism of action. Dapagliflozin lowers blood glucose by promoting glycosuria and provides cardiovascular and renal benefits, leading to its widespread use. However, given the polypharmacy typical in diabetic patients, understanding the drug-drug interactions (DDIs) of dapagliflozin is crucial for optimizing patient care. This review explores the pharmacokinetics and pharmacodynamics of dapagliflozin and potential drug-drug interactions (DDIs). Interactions with other glucose-lowering agents and cardiovascular drugs are noted, with potential impacts on efficacy and safety. The review also addresses interactions with UGT modulators, CYP3A4 inducers, and inhibitors, emphasizing the need for careful management to avoid adverse effects and optimize therapy

Published Paper   E-Certificate

"DRUG-DRUG INTERACTIONS WITH DAPAGLIFLOZIN: A REVIEW", IJNRD - INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (www.IJNRD.org), ISSN:2456-4184, Vol.9, Issue 8, page no.c205-c210, August-2024, Available :https://ijnrd.org/papers/IJNRD2408223.pdf

Volume 9 Issue 8, August-2024

Pages : c205-c210

Paper Reg. ID: IJNRD_226711

Published Paper Id: IJNRD2408223

Downloads: 000121216

Research Area: Engineering

Country: CALICUT, KERALA, India

Published Paper PDF: https://ijnrd.org/papers/IJNRD2408223.pdf

Published Paper URL: https://ijnrd.org/viewpaperforall?paper=IJNRD2408223

Journal Name: INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT(IJNRD)

ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Publisher: IJNRD (IJ Publication) Janvi Wave

This work is licensed under a Creative Commons Attribution 4.0 International License and The Open Definition

Call For Paper - Volume 10 | Issue 8 | August 2025

IJNRD is Scholarly open access journals, Peer-reviewed, and Refereed Journals, High Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool), Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI) with Open-Access Publications.

INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) aims to explore advances in research pertaining to applied, theoretical and experimental Technological studies. The goal is to promote scientific information interchange between researchers, developers, engineers, students, and practitioners working in and around the world. IJNRD will provide an opportunity for practitioners and educators of engineering field to exchange research evidence, models of best practice and innovative ideas.

Indexing In Google Scholar, SSRN, ResearcherID-Publons, Semantic Scholar | AI-Powered Research Tool, Microsoft Academic, Academia.edu, arXiv.org, Research Gate, CiteSeerX, ResearcherID Thomson Reuters, Mendeley : reference manager, DocStoc, ISSUU, Scribd, and many more

How to submit the paper?

Important Dates for Current issue

Paper Submission Open For: August 2025

Current Issue: Volume 10 | Issue 8

Last Date for Paper Submission: Till 31-Aug-2025

Notification of Review Result: Within 1-2 Days after Submitting paper.

Publication of Paper: Within 01-02 Days after Submititng documents.

Frequency: Monthly (12 issue Annually).

Journal Type: International Peer-reviewed, Refereed, and Open Access Journal.

Subject Category: Research Area